Hypervesiculating Bt OMVs for Sustained Gut Enzyme Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current remedies for chronic intestinal conditions like lactose intolerance provide short-lived relief, and the mechanisms of outer membrane vesicle (OMV) biogenesis in Bacteroides spp. are poorly understood, particularly in addressing the technical challenges of existing technologies, which fail to effectively address the technical challenges of addressing the technical problem of therapeutic enzyme delivery.
Innovation Solution
Engineering a Bacteroides thetaiotaomicron strain with mutated dual membrane-spanning anti-sigma factor (Dma) proteins to overproduce OMVs, loading therapeutic enzymes into these vesicles, and administering them to the gut microbiome to treat conditions such as lactose intolerance, phenylketonuria, and inflammatory bowel disease.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If exogenous lactase enzyme is administered to treat lactose intolerance, then temporary relief is provided, but the effect is short-lived and requires repeated dosing
Solution Approach 1:
The patent employs self-replicating Bacteroides bacteria that continuously produce and secrete lactase enzyme in the gut. The bacteria multiply and persist in the gastrointestinal tract, providing ongoing enzyme supply without requiring repeated external dosing. This transforms the temporary relief from exogenous enzyme into sustained endogenous production by the engineered microbiome.
Solution Approach 2:
The therapeutic bacteria are administered in advance to colonize the gut before exposure to lactose-containing foods. The bacteria establish themselves and begin producing lactase enzyme proactively, so that when the patient consumes dairy products, the enzyme is already present and continuously available, rather than being administered reactively at the time of need.
2Productivity
If Bacteroides strain is engineered to overproduce OMVs, then therapeutic enzyme delivery is enhanced, but the mechanism of OMV biogenesis becomes more complex to understand and control
Solution Approach 1:
The patent modifies specific genetic parameters of the Bacteroides strain, particularly in the dma operon (dual membrane-spanning anti-sigma factors), to regulate OMV biogenesis. By changing the expression levels or activity of these regulatory proteins, the bacteria's natural vesiculation process is enhanced without requiring complete reconstruction of the biogenesis machinery. This allows increased OMV production while maintaining the organism's natural regulatory framework.
Solution Approach 2:
The patent extracts and utilizes the natural OMV biogenesis pathway of Bacteroides, which already exists as a regulated cellular process. Rather than introducing entirely artificial vesicle production mechanisms, the invention harnesses and optimizes the bacteria's endogenous OMV formation system, particularly by modifying regulatory elements like the dma operon that naturally control this process.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The engineered Bacteroides thetaiotaomicron strain effectively increases and maintains therapeutic enzyme concentration in the gut, providing longer-term relief for chronic intestinal conditions by actively producing OMVs with tailored cargo.
Implementation Method 1
Vesiculation is a process by which cells utilize membranous compartments to traffic cellular contents. In eukaryotes, vesiculation, in the form of the trans-Golgi network, exosomes, and other extracellular vesicles, has been extensively studied. However, much less is known about vesiculation in bacteria.
Implementation Method 2
Outer Membrane Vesicles (OMVs) are small, spherical structures generated by the active blebbing of the outer membrane (OM) in gram-negative bacteria.
Data Source
AI summary
Engineered Bacteroides thetaiotaomicron (Bt) strains, including deletion mutant strains, and methods of use thereof are provided. Methods of delivering a therapeutic compound to a gut microbiome of a subject include generating an engineered Bacteroides thetaiotaomicron (Bt) strain to overproduce outer membrane vesicles (OMVs); loading a target therapeutic compound into the OMVs; and colonizing the gut microbiome of the subject with the engineered Bt strain. In some embodiments, the subject has at least one of lactose intolerance, phenylketonuria, inflammatory bowel disease, and a chronic intestinal condition.